Folate metabolism: a re-emerging therapeutic target in haematological cancers

MM Zarou, A Vazquez, G Vignir Helgason - Leukemia, 2021 - nature.com
Folate-mediated one carbon (1C) metabolism supports a series of processes that are
essential for the cell. Through a number of interlinked reactions happening in the cytosol …

FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review

AK Abdel-Aziz, EME Dokla, MK Saadeldin - Critical Reviews in Oncology …, 2023 - Elsevier
FMS-like tyrosine kinase 3 (FLT3) mutations occur in almost 30% of acute myeloid leukemia
(AML) patients. Despite the initial clinical efficacy of FLT3 inhibitors, many treated AML …

C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia

M Sabatier, R Birsen, L Lauture, S Mouche, P Angelino… - Cancer Discovery, 2023 - AACR
Although transcription factor CCAAT-enhancer binding protein α (C/EBPα) is critical for
normal and leukemic differentiation, its role in cell and metabolic homeostasis is largely …

A ferroptosis-inducing and leukemic cell-targeting drug nanocarrier formed by redox-responsive cysteine polymer for acute myeloid leukemia therapy

Y Yu, Y Meng, X Xu, T Tong, C He, L Wang, K Wang… - ACS …, 2023 - ACS Publications
Ferroptosis is an alternative strategy to overcome chemoresistance, but effective therapeutic
approaches to induce ferroptosis for acute myeloid leukemia (AML) treatment are limited …

[HTML][HTML] NAT10-mediated mRNA N4-acetylcytidine reprograms serine metabolism to drive leukaemogenesis and stemness in acute myeloid leukaemia

S Zhang, F Huang, Y Wang, Y Long, Y Li, Y Kang… - Nature Cell …, 2024 - nature.com
RNA modification has emerged as an important epigenetic mechanism that controls
abnormal metabolism and growth in acute myeloid leukaemia (AML). However, the roles of …

Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death

K Woodley, LS Dillingh, G Giotopoulos… - Nature …, 2023 - nature.com
Resistance to standard and novel therapies remains the main obstacle to cure in acute
myeloid leukaemia (AML) and is often driven by metabolic adaptations which are …

Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets

SK Mishra, SE Millman, L Zhang - Blood, 2023 - ashpublications.org
Metabolic rewiring and cellular reprogramming are trademarks of neoplastic initiation and
progression in acute myeloid leukemia (AML). Metabolic alteration in leukemic cells is often …

Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor–mediated synergistic antileukemic actions

P Zhang, LT Brinton, M Gharghabi, S Sher… - Science …, 2022 - science.org
Using a genome-wide CRISPR screen, we identified CDK9, DHODH, and PRMT5 as
synthetic lethal partners with gilteritinib treatment in fms-like tyrosine kinase 3 (FLT3) …

IGF2BP2 promotes lncRNA DANCR stability mediated glycolysis and affects the progression of FLT3-ITD+ acute myeloid leukemia

S Wu, C Chi, S Weng, W Zhou, Z Liu - Apoptosis, 2023 - Springer
Internal tandem duplication (ITD) is the most common type of FLT3 mutation (FLT3-ITD),
accounting for about 25% of AML patients. The expression of DANCR in FLT3-ITD AML had …

Synthetic lethal strategies for the development of cancer therapeutics

NYL Ngoi, D Gallo, C Torrado, M Nardo… - Nature Reviews …, 2024 - nature.com
Synthetic lethality is a genetic phenomenon whereby the simultaneous presence of two
different genetic alterations impairs cellular viability. Importantly, targeting synthetic lethal …